首页> 外文期刊>Gut Pathogens >Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice
【24h】

Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice

机译:枯草芽孢杆菌GBI-30(BC30)改善了艰难梭菌诱导的小鼠结肠炎的指标

获取原文
           

摘要

Background Probiotics have beneficial effects in rodent models of Clostridium difficile (C. diffiicle)-induced colitis. The spore forming probiotic strain Bacillus Coagulans GBI-30, 6086 (BC30) has demonstrated anti-inflammatory and immune-modulating effects in vitro. Our goal was to determine if BC30 improved C. difficile-induced colitis in mice. Starting on study day 0, female C57BL/6 mice were dosed by oro-gastric gavage for 15 days with vehicle (saline) or BC30 (2 × 109 CFU per day). Mice in the C. difficile groups received an antibiotic mixture (study days 5 to 8 in the drinking water), and clindamycin (10 mg/kg, i.p., on study day 10). The C. difficile strain VPI 10463 was given by gavage at 104 CFU to induce colitis on day 11. On day 16, stools and colons were collected for further analyses. Results All mice treated with BC30 survived on study day 13, while two mice treated with vehicle did not survive. On day 12, a significant difference (p = 0.0002) in the percentage of mice with normal stools (66.7%) was found in the BC30/C. difficile group, as compared to the vehicle/C. diffcile group (13.0%). On study day 16, 23.8% of mice treated with BC30 had normal stools, while this value was 0% with vehicle treatment (p value = 0.0187). On this day, the stool consistency score for the BC30/C. difficile group (1.1 ± 0.2) was significantly lower (p < 0.05) than for the vehicle/C. difficile cohort (1.9 ± 0.2). BC30 modestly attenuated the colonic pathology (crypt damage, edema, leukocyte influx) that was present following C. difficile infection. Colonic MIP-2 chemokine contents (pg/2 cm colon) were: 10.2 ± 0.5 (vehicleo C. difficile), 24.6 ± 9.5 (vehicle/C. difficile) and 16.3 ± 4.3 (BC30/C. difficle). Conclusion The probiotic BC30 improved some parameters of C. difficile-induced colitis in mice. BC30 prolonged the survival of C. diffiicle infected mice. Particularly, this probiotic improved the stool consistency of mice, in this infectious colitis model.
机译:背景技术益生菌在艰难梭状芽胞杆菌(C. diffiicle)诱导的结肠炎的啮齿动物模型中具有有益的作用。芽孢形成益生菌菌株芽孢杆菌GBI-30,6086(BC30)在体外具有抗炎和免疫调节作用。我们的目标是确定BC30是否能改善小鼠艰难梭菌诱导的结肠炎。从研究第0天开始,对雌性C57BL / 6小鼠经口胃管灌胃15天,溶媒(盐水)或BC30(每天2×109 CFU)。艰难梭菌组中的小鼠接受抗生素混合物(在饮用水中研究5至8天)和克林霉素(10 mg / kg,在研究第10天腹腔注射)。在第11天通过104 CFU的管饲法给予艰难梭菌菌株VPI 10463,以诱导结肠炎。在第16天,收集粪便和结肠进行进一步分析。结果用BC30治疗的所有小鼠在研究第13天都存活,而用媒介物治疗的两只小鼠没有存活。在第12天,在BC30 / C中发现了具有正常粪便的小鼠百分比(66.7%)的显着差异(p = 0.0002)。相对于媒介物/ C而言,难辨认群体。困难组(13.0%)。在研究第16天,用BC30治疗的小鼠中有23.8%的粪便正常,而用赋形剂治疗时该值为0%(p值= 0.0187)。在这一天,BC30 / C的粪便稠度评分。难治组(1.1±0.2)显着低于媒介物/ C(p <0.05)。困难队列(1.9±0.2)。 BC30适度减弱了艰难梭菌感染后出现的结肠病理(隐窝损害,水肿,白细胞涌入)。结肠MIP-2趋化因子含量(pg / 2 cm结肠)为:10.2±0.5(载体/无艰难梭菌),24.6±9.5(载体/艰难梭菌)和16.3±4.3(BC30 /艰难梭菌)。结论益生菌BC30改善了艰难梭菌诱导的小鼠结肠炎的某些参数。 BC30延长了感染艰难梭菌的小鼠的存活。特别地,在这种感染性结肠炎模型中,这种益生菌改善了小鼠的粪便稠度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号